CAS
RCUS icon

Coppell Advisory Solutions’s Arcus Biosciences RCUS Stock Holding History

Coppell Advisory Solutions’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,413
Closed -$21.1K – 1500
2024
Q4 		$21.1K Hold
1,413
– – ﹤0.01% 869
2024
Q3 		$21.8K Hold
1,413
– – ﹤0.01% 838
2024
Q2 		$21.5K Buy
+1,413
New +$22.8K ﹤0.01% 757
2023
Q4 		$48.1K Buy
2,519
+2,319
+1,160% +$37.1K 0.01% 506
2023
Q3 		$4.14K Hold
200
– – ﹤0.01% 745
2023
Q2 		$3.94K Buy
+200
New +$3.81K ﹤0.01% 897
2023
Q1 		– Sell
-200
Closed -$4.14K – 863
2022
Q4 		$4.14K Buy
+200
New +$5.5K ﹤0.01% 749

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Coppell Advisory Solutions's RCUS Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Arcus Biosciences (RCUS) in Q1 2025, closing a stake of 1,413 shares — an estimated $21.1K sold.

Coppell Advisory Solutions first reported a position in RCUS in Q4 2022 and held it in 7 quarters. The position peaked at $48.1K in Q4 2023. 186 funds tracked by Wall St. Rank hold RCUS as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Arcus Biosciences position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 1,413 Arcus Biosciences shares in Q1 2025, an estimated $21.1K.
  • Coppell Advisory Solutions first reported a position in Arcus Biosciences in Q4 2022 and held it in 7 quarters.
  • Coppell Advisory Solutions's Arcus Biosciences position peaked at $48.1K in Q4 2023.
  • 186 funds tracked by Wall St. Rank held Arcus Biosciences as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.